Modern biomarkers in cardiology
https://doi.org/10.21518/2079-701X-2018-16-118-123
Abstract
Modern clinical practice requires obligatory use of results of laboratory researches, international experience demonstrates the need of the clinic in laboratory information for making up to 70% of medical decisions. Described a large number of biomarkers of cardiovascular diseases, high diagnostic efficiency with sufficient level of evidence is shown not for all. In article the possibilities of a modern laboratory in determining markers of myocardium damage (troponins, hFABP), myocardial stress (natriuretic peptides) and neurohumoral regulation (copeptin), the diagnostic and predictive importance of these researches are considered.
References
1. Menshikov VV. Clinical safety of the patient and reliability of laboratory information (lecture). Klinicheskaya Laboratornaya Diagnostika, 2013, 6: 29-36
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred defini tions and conceptual framework. Clinical Pharmacolo gy & Therapeutics, 2001 Mar, 69(3): 89-95.
3. Kumar M and Sarin SK. Biomarkers of diseases in medicine. Current Trends in Science. Platinum Jubilee Special. 2009: 403-417.
4. 2015 ESC Guidel ines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J, 2016, 37(3): 267-315.
5. Ostrovsky OV, Tkacheva VV, Ostrovskaya VO. Laboratory markers of myocardial damage in modern cardiology. Spetsvypusk Laboratoriya, 2013, 2: 31-36.
6. Giannitsis E, Mockel M. Clinical Utility of Copeptin and troponin in the Emergency depertment. 2017.
7. Garg A et al. Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review. Cardiology, 2017, 136(3): 192-203.
Review
For citations:
Dymova OV. Modern biomarkers in cardiology. Meditsinskiy sovet = Medical Council. 2018;(16):118-123. (In Russ.) https://doi.org/10.21518/2079-701X-2018-16-118-123
Views:
966
Email this article 